The search for a COVID-!9 drugs that could triumph over the Virus is still afoot, with its ever-increasing intensity. Many of the high-end countries like the U.S have found luck with Oral Antiviral therapy ‘PAXLOVID’ which is authorized for emergency use in the US and other countries amongst high-risk adults and pediatric patients. This COVID-19 oral treatment has shown an 89% reduction in the risk of hospitalization or death for any cause within three days after the onset of symptoms compared to placebo.
But after its successful authorization and to make it cost-effective, a Bengaluru-based pharmaceutical company has announced a sub-license agreement with the Medicines Patent Pool (MPP) to commercialize the generic version of U.S COVID-19 oral treatment in low and middle-income countries. This generic version will consist of Nirmatrelvir tablets, co-packaged and co-administered with Ritonavir tablets, and is a SARS-CoV-2 main protease inhibitor oral antiviral therapy. Commercialization of this generic, prove to be one of the best moves by a pharmaceutical company during the COVID period.
This could act as a motivation to other pharmaceutical companies working in the anti-viral segment to upgrade their scientific and marketing skills. For any Pharmaceutical company to move uphill, the knowledge of the latest trends and advances in the pharmaceutical market plays a key role and we at SI Research & Solutions, cater to all your Market insight needs with extensive research and a better understanding of the pharmaceutical segment.
Bring an end to your quest and reach out to us at, vijay@siinsights.com or call +917506221809
Leave a comment